RSB Spine v. Orthofix & SeaSpine: Cervical Fusion Patent Dismissed With Prejudice in 109 Days
RSB Spine, LLC brought a patent infringement action against Orthofix Medical and three SeaSpine entities in the Eastern District of Texas, asserting US9713537B2 over stand-alone cervical fixation devices used in ACDF procedures. The case closed in just 109 days when RSB Spine voluntarily dismissed all claims with prejudice, with each party bearing its own costs.
Swift with-prejudice exit in the spinal implant IP space
On 26 October 2023, RSB Spine, LLC filed a patent infringement action in the Eastern District of Texas (Case No. 4:23-cv-00959) before Judge Amos L. Mazzant. The defendants were Orthofix Medical, Inc. and three SeaSpine-affiliated entities: SeaSpine Holdings Corp., SeaSpine Orthopedics Corp., and SeaSpine, Inc. At issue was US9713537B2, a patent covering stand-alone cervical fixation technology used in anterior cervical interbody fusion (ACDF) procedures. Accused products included the LoneStar Cervical Stand Alone System, the Complete Cervical IBD System, the Meridian with Reef A device, and ACS devices.
The case closed on 12 February 2024, just 109 days after filing. RSB Spine filed a stipulation of dismissal with prejudice under Federal Rule of Civil Procedure 41(a)(1)(A)(i), covering all claims against all four defendants. Critically, the stipulation also provided that each party would bear its own costs and attorney’s fees, meaning no financial liability was imposed on either side by court order. A with-prejudice dismissal extinguishes RSB Spine’s right to reassert the same claims against these defendants in any future action.
A resolution in under four months — before any substantive court ruling — suggests the dispute was resolved or abandoned well before claim construction or merits briefing. The public record does not disclose whether a private settlement was reached; the mutual cost-bearing provision is consistent with either a confidential settlement or a strategic decision by RSB Spine to withdraw. The early exit leaves the validity and infringement of US9713537B2 formally untested, meaning competitors operating in the cervical stand-alone fusion segment face no judicial guidance from this litigation.
Filing to dismissal in 109 days
109 days — faster than the majority of comparable district court patent infringement cases
Dismissed with prejudice — all claims extinguished, costs split
Rule 41(a)(1)(A)(i): plaintiff-initiated dismissal
RSB Spine invoked Fed. R. Civ. P. 41(a)(1)(A)(i), which permits a plaintiff to dismiss an action without a court order by filing a notice before the opposing party serves an answer or a motion for summary judgment. This mechanism gives the plaintiff full control of the exit and requires no judicial approval, consistent with the case closing swiftly without substantive rulings.
No court order requiredWith prejudice: permanent bar on refiling these claims
A dismissal with prejudice operates as a final adjudication on the merits under res judicata principles. RSB Spine is permanently barred from reasserting the same infringement claims against Orthofix, SeaSpine Holdings, SeaSpine Orthopedics, and SeaSpine, Inc. based on US9713537B2. This offers the defendants durable protection against re-litigation of the same accused products, even if ownership of the patent changes.
Permanent claim barMutual cost-bearing: no financial winner declared
The stipulation expressly provides that each party bears its own attorney’s fees and costs. This is notable in a case where defendants could potentially have sought fees under 35 U.S.C. § 285 if the case were deemed exceptional. The mutual cost-bearing arrangement suggests a negotiated outcome rather than a unilateral capitulation, though the public record does not confirm or deny a confidential settlement.
No § 285 fee awardUS9713537B2 validity remains judicially untested
Because the case ended before any substantive rulings — no claim construction order, no validity determination, no infringement finding — US9713537B2 emerges from this litigation with its claims intact but uninterpreted by a court. Other parties in the cervical stand-alone fusion space cannot rely on any judicial guidance from this case when assessing their own freedom-to-operate or invalidity arguments.
No claim construction issuedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | RSB Spine, LLC | Company | Spinal implant IP holding company — asserting US9713537B2 covering cervical fixation devicesSearch in Eureka ↗ |
| Defendant | Orthofix Medical, Inc. | Company | Orthofix Medical and three SeaSpine entities — makers of cervical stand-alone fusion implant systemsSearch in Eureka ↗ |
| Plaintiff counsel | Gregory Phillip Love | Attorney | Counsel for RSB Spine, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Mark Douglas Siegmund | Attorney | Counsel for RSB Spine, LLCSearch in Eureka ↗ |
| Presiding judge | Judge Amos L. Mazzant | Chief Judge | Texas Eastern District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The stipulation invokes Rule 41(a)(1)(A)(i), meaning RSB Spine acted before any responsive pleading was filed — the broadest form of plaintiff-controlled exit. The with-prejudice designation, unusually specific for a voluntary early dismissal, permanently extinguishes RSB Spine’s claims against all four named defendants. The mutual cost-bearing clause forecloses any § 285 exceptional-case fee motion. Taken together, the phrasing suggests a negotiated resolution rather than a unilateral withdrawal, though no terms beyond costs are disclosed in the public record.
US9713537B2 — Stand-alone anterior cervical interbody fusion device
US9713537B2 (application number US15/413945) protects a stand-alone cervical fixation device designed for anterior cervical interbody fusion (ACDF) procedures in skeletally mature patients with degenerative disc disease at a single cervical level from C2 to T1. Stand-alone cervical fixation systems integrate the interbody spacer and fixation mechanism into a single implant, eliminating the need for a separate anterior cervical plate. This design approach has been a competitive focus area in spine surgery as surgeons seek to reduce operative complexity and implant profile.
The patent’s claims sit at the intersection of biomechanical design and minimally invasive spine surgery — a segment where product differentiation is frequently contested through IP. The accused products from Orthofix and SeaSpine — including the LoneStar CSA System, Complete Cervical IBD System, and Meridian with Reef A — represent commercially significant ACDF product lines. Because no court has construed the claims of US9713537B2 or ruled on infringement, the patent remains a viable enforcement tool against other cervical stand-alone device manufacturers operating in this space.
Should your ACDF device portfolio be cleared against US9713537B2?
Any company designing, manufacturing, or distributing stand-alone anterior cervical interbody fusion devices — particularly those integrating fixation and spacer functions in a single implant — should assess exposure to US9713537B2. This case did not produce a claim construction order, so the patent’s scope has not been judicially narrowed. The dismissal with prejudice only protects Orthofix and the three SeaSpine entities; all other market participants remain potentially in scope.
PatSnap Eureka’s FTO Search Agent can map the claims of US9713537B2 against your specific device geometry and fixation architecture, identifying design-around opportunities and prior art that could support an IPR petition. Claim monitoring alerts can also flag any continuation or divisional applications deriving from US9713537B2 before they issue — critical for early-stage ACDF product development where design changes are still feasible.
Run a freedom-to-operate analysis on US9713537B2 to assess your product’s exposure
Run FTO in Eureka →Similar patent cases in spinal implant and ACDF device litigation
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the spinal implant IP landscape
A fast, with-prejudice exit in the Eastern District of Texas raises pointed questions about enforcement strategy and product risk in the cervical fusion segment.
Early dismissal leaves the patent’s enforceability an open question
No court ever ruled on whether US9713537B2 is valid or infringed. For competitors in the cervical stand-alone fusion space, this means the patent retains its full presumption of validity. Any company selling ACDF stand-alone devices should treat this patent as an active risk and conduct a formal FTO analysis rather than relying on this case as clearance.
Eastern District of Texas remains a high-stakes venue for medtech IP
RSB Spine’s choice of the Eastern District of Texas — a plaintiff-preferred venue — likely influenced how quickly defendants engaged. The swift with-prejudice resolution, before any answer was filed, suggests defendants moved to address the dispute promptly. Medtech companies should anticipate this venue’s procedural pace when building litigation response strategies.
RSB v Orthofix — key questions answered
The case was dismissed with prejudice on 12 February 2024, 109 days after filing. RSB Spine filed a voluntary stipulation of dismissal under Fed. R. Civ. P. 41(a)(1)(A)(i) covering all claims against all four defendants. Each party agreed to bear its own costs and attorney’s fees. No substantive rulings on validity or infringement were issued.
RSB Spine asserted US9713537B2 (application US15/413945), a patent covering stand-alone cervical fixation devices for use in anterior cervical interbody fusion (ACDF) procedures. The accused products included the LoneStar Cervical Stand Alone System, Complete Cervical IBD System, Meridian with Reef A devices, and ACS devices.
No. A dismissal with prejudice only bars RSB Spine from refiling the same claims against the four named defendants: Orthofix Medical, SeaSpine Holdings Corp., SeaSpine Orthopedics Corp., and SeaSpine, Inc. Other companies selling cervical stand-alone fusion devices are not protected by this ruling and remain potentially exposed to claims under US9713537B2.
The public record does not disclose the reason. The 109-day resolution before any responsive pleading, combined with a mutual cost-bearing provision, is consistent with a confidential settlement or licensing agreement, though this cannot be confirmed from available documents. It is also possible RSB Spine conducted a strategic reassessment of its litigation position after filing.
The case was filed in the United States District Court for the Eastern District of Texas (Case No. 4:23-cv-00959). Chief Judge Amos L. Mazzant was assigned to the case. The Eastern District of Texas is a frequently chosen venue by patent plaintiffs due to its established patent docket and historically plaintiff-friendly reputation.
PatSnap Eureka searches patents and litigation data to answer instantly.